Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06287918
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-11
First Post:
2024-02-22
Brief Title:
A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
Sponsor:
3H Suzhou Pharmaceuticals Co Ltd
Organization:
3H Suzhou Pharmaceuticals Co Ltd
Study Overview
Official Title:
A First-in-human Open-label Dose Escalation and Expansion Study Evaluating the Safety Tolerability Pharmacokinetics and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is being conducted to evaluate the safety tolerability efficacy pharmacokinetics and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations Patients will be enrolled in two stages dose escalation stage Stage I and expansion stage Stage II
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None